Clinical trial NCT04740801: Electrical Coupling Information From The RHYTHMIA HDx Mapping System and DIRECTSENSE Technology In The Treatment of Paroxysmal Atrial Fibrillation (LOCALIZE CF)
Official title: Electrical Coupling Information From The RHYTHMIA HDx Mapping System and DIRECTSENSE Technology In The Treatment of Paroxysmal Atrial Fibrillation: A Non-Randomized Prospective Study With Contact Force
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Paroxysmal Atrial Fibrillation
Lead sponsor: Boston Scientific Corporation
Sponsor class: INDUSTRY
First posted: 2021-02-05
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The objective of this study is to evaluate whether local impedance (DIRECTSENSE™) drop on the INTELLANAV STABLEPOINT™ ablation catheter is associated with late pulmonary vein (PV) reconnections and durable conduction block in patients undergoing de novo PV isolation (PVI) for treatment of paroxysmal atrial fibrillation (PAF).


Eligibility criteria: Inclusion Criteria:

1. History of recurrent, symptomatic, paroxysmal atrial fibrillation (PAF), defined as atrial fibrillation (AF) that terminates spontaneously or with intervention (either procedure or drug therapy) within seven days of onset. Minimum documentation includes at least one AF episode electrocardiographically documented and at least one additional symptomatic recurrence with or without electrocardiographic documentation, within 365 days prior to enrollment.
2. Subjects who are eligible for an ablation procedure for paroxysmal AF according to international and local guidelines on catheter ablation of AF.
3. Subjects refractory or intolerant to at least one Beta Blocker, Calcium Channel Blocker, class I or III antiarrhythmic medication taken for the treatment of AF/AT (Atrial Tachycardia)/AFL (Atrial Flutter) or contraindicated to any class I or III antiarrhythmic medications, Beta Blocker or Calcium Channel Blocker.
4. Subjects who are willing and capable of providing informed consent.
5. Subjects who are willing and capable of participating in all testing associated with this clinical investigation at an approved clinical investigational center.
6. Subjects whose age is 18 years or above, or who are of legal age to give informed consent specific to local and national law.

Exclusion Criteria:

1. Any known contraindication to an AF ablation or anticoagulation
2. Continuous AF lasting longer than seven days from onset (no episodes within 365 days from enrollment)
3. History of previous LA ablation or surgical treatment for AF/AT/AFL
4. AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause
5. Subjects with life expectancy ≤ 6 months
6. Structural heart disease, heart conditions, or implanted devices as described below:

   1. Left ventricular ejection fraction \< 35% based on the most recent imaging (≤ 180 days prior to enrollment)\*
   2. LA diameter \> 5.5 cm or LA volume \>50 ml/m² indexed based on the most recent imaging (≤ 180 days prior to enrollment)\*
   3. Heart failure with New York Heart Association (NYHA) Class III or IV
   4. Previous cardiac surgery (e.g. ventriculotomy or atriotomy, CABG, PTCA, stent procedure) within 90 days prior to enrollment
   5. Implantable cardiac device procedures (e.g. PM, ICD, CRT) within 30 days prior to enrollment
   6. Severe valvular disease or presence of a prosthetic - mechanical or biological - heart valve in the LA (not including valve repair and annular rings)
   7. Severe mitral valve regurgitation or stenosis
   8. Known or pre-existing severe pulmonary vein stenosis
   9. Interatrial baffle, closure device, patch, or patent foramen ovale (PFO) occluder
   10. Presence of LA appendage occlusion device
   11. Presence of any pulmonary vein stents
   12. Unstable angina or ongoing myocardial ischemia
   13. Previous myocardial infarction within 90 days prior to enrollment
   14. Vena cava embolic protection filter devices and/or known femoral thrombus;
   15. Known left atrial thrombus, myxoma, or intracardiac mural thrombus
7. History of blood clotting or bleeding disease
8. Any prior history of documented cerebral infarct, TIA, or systemic embolism \[excluding a post-operative deep vein thrombosis (DVT)\] ≤180 days prior to enrollment
9. Active systemic infection
10. Pregnant, lactating (current or anticipated during study follow up), or women of childbearing potential who are, or plan to become, pregnant during the time of the study (method of assessment upon physician's discretion)
11. Subjects who are currently enrolled in any other concurrent study, with the exception of local mandatory governmental registries and observational studies/registries, without written approval from the sponsor

Primary outcomes:
measure: Association between Local Impedance drop values and PV reconnections
timeFrame: 0-3 months
Secondary outcomes:
measure: Association between Local Impedance drop values and acute PV reconnections
timeFrame: 0-1 month
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: Vivantes Klinikum Am Urban
city: Karlsruhe
country: Germany
facility: Städtisches Klinikum Karlsruhe
city: Mercogliano
country: Italy
facility: Casa di Cura Montevergine S.p.A.
state: Avellino
city: Milano
country: Italy
facility: Centro Cardiologico Monzino
city: Pamplona
country: Spain
facility: Clinica Universidad de Navarra
Study officials:
affiliation: Clinica Universitaria de Navarra
name: Ignacio Garcia Bolao, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Vivantes Klinikum am Urban
name: Hüseyin Ince, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Casa Di Cura 'Montevergine' S.P.A.
name: Francesco Solimene, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Staedtisches Klinikum Karlsruhe
name: Armin Luik, MD
role: PRINCIPAL_INVESTIGATOR
References: